PIONEER 6 achieved its primary objective, confirming noninferiority for oral semaglutide versus placebo for cardiovascular safety in a high-risk population, with a non-significant 21 percent reduction in three-point MACE over a median follow-up period of just under 16 months, said lead investigator Mansoor Husain, MD, Director of the Toronto General Hospital Research Institute, Executive Director of the Ted Rogers Centre for Heart Research, and Professor of Medicine at the University of Toronto
The result is the same whether you call it thinning, pattern baldness, or just getting older
Monitoring kidney function, staying hydrated, and using appropriate dosing helps maintain safety
MSH 11-13 / Lys-Pro-Val compound record
But emideltide, under consideration for opioid withdrawal, chronic insomnia, and narcolepsy, failed voting passage by a tally of 6-7
In Dubai, physicians frequently recommend a series of treatments to achieve visible results